CBD and beta-caryophyllene together produced synergistic pain relief and antidepressant effects in mice

In a chronic inflammatory pain model (CFA-induced), the combination of CBD and beta-caryophyllene (BCP) produced synergistic pain-relieving effects that exceeded either compound alone. The combination also exhibited antidepressant properties. Immunohistochemistry showed the combination significantly reduced neuroinflammation, and proteomics revealed downregulation of inflammation-related proteins by the combination compared to individual effects of CBD or BCP.

Complete Freund's Adjuvant (CFA) chronic inflammatory pain model in mice. Battery of pain and depression-like behavior tests. Proteomics and immunohistochemistry to explore mechanisms. Compared CBD alone, BCP alone, and the combination.

Chronic pain and depression frequently co-occur but are typically treated separately. Finding a combination that addresses both simultaneously through anti-inflammatory mechanisms could offer a more integrated treatment approach, particularly if it can reduce reliance on opioids.

Beta-caryophyllene is a terpene found naturally in cannabis and many other plants that selectively activates CB2 receptors. This study supports the "entourage effect" concept that cannabis components beyond THC and CBD contribute meaningfully to therapeutic outcomes, and identifies a specific combination with translational potential.

Animal study results may not translate to humans. CFA model represents one type of chronic pain. Specific doses and the optimal ratio of CBD to BCP were not fully characterized. No long-term safety or efficacy data.